Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug122 | ARBIDOL 100 MG KAPSUL Wiki | 0.21 |
| drug804 | CT-imaging Wiki | 0.21 |
| drug8 | 0.12% Chlorhexidine oral/nasal rinse Wiki | 0.21 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3508 | Saline oral/nasal rinse Wiki | 0.21 |
| drug2488 | NOX66 Wiki | 0.21 |
| drug4693 | rapid salivary test Wiki | 0.21 |
| drug132 | ARFC mask Wiki | 0.21 |
| drug1525 | Fenofibrate Wiki | 0.21 |
| drug1506 | Family Nurture Intervention (FNI) Wiki | 0.21 |
| drug3216 | RBA-2 Wiki | 0.21 |
| drug2198 | Low fat "standard care" control breakfast Wiki | 0.21 |
| drug4520 | iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System Wiki | 0.21 |
| drug10 | 0.5% Povidone/Iodine oral/nasal rinse Wiki | 0.21 |
| drug145 | ATAFENOVIR 200 MG KAPSUL Wiki | 0.21 |
| drug2203 | Low-Carb High-Fat breakfast Wiki | 0.21 |
| drug3111 | Prone position ventilation Wiki | 0.21 |
| drug2077 | L-ascorbic acid Wiki | 0.15 |
| drug1168 | Data record Wiki | 0.15 |
| drug3566 | Selinexor Wiki | 0.12 |
| drug4172 | Usual care Wiki | 0.10 |
| drug1060 | Convalescent plasma Wiki | 0.04 |
| drug1775 | Hydroxychloroquine Wiki | 0.02 |
| drug2916 | Placebo Wiki | 0.01 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D010510 | Periodontal Diseases NIH | 0.21 |
| D012893 | Sleep Wake Disorders NIH | 0.12 |
| D018352 | Coronavirus Infections NIH | 0.11 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.11 |
| D000163 | Acquired Immunodeficiency Syndrome NIH | 0.10 |
| D016769 | Embolism and Thrombosis NIH | 0.10 |
| D058186 | Acute Kidney Injury NIH | 0.08 |
| D008107 | Liver Diseases NIH | 0.07 |
| D007238 | Infarction NIH | 0.06 |
| D015658 | HIV Infections NIH | 0.05 |
| D011655 | Pulmonary Embolism NIH | 0.05 |
| D004617 | Embolism NIH | 0.05 |
| D007239 | Infection NIH | 0.05 |
| D011024 | Pneumonia, Viral NIH | 0.05 |
| D009203 | Myocardial Ischemia NIH | 0.05 |
| D003141 | Communicable Diseases NIH | 0.05 |
| D013927 | Thrombosis NIH | 0.04 |
| D000860 | Hypoxia NIH | 0.04 |
| D014947 | Wounds and Injuries NIH | 0.04 |
| D016638 | Critical Illness NIH | 0.03 |
| D011014 | Pneumonia NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000704 | Periodontitis HPO | 0.21 |
| HP:0001919 | Acute kidney injury HPO | 0.08 |
| HP:0001392 | Abnormality of the liver HPO | 0.07 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002204 | Pulmonary embolism HPO | 0.05 |
| HP:0001658 | Myocardial infarction HPO | 0.05 |
| HP:0001907 | Thromboembolism HPO | 0.04 |
| HP:0012418 | Hypoxemia HPO | 0.04 |
| HP:0002090 | Pneumonia HPO | 0.02 |
Navigate: Correlations HPO
There are 23 clinical trials
COVID-19 may cause another world-wide epidemic. This study is divided into 2 arms: (1) Prospective longitudinal observational study involving patients with laboratory-confirmed COVID-19 and (2) Retrospective study on patients with laboratory-confirmed COVID-19. Arm 1: We will collect EDTA blood, stool samples, rectal swab, urine, saliva, and specimens from upper respiratory tract (nasopharyngeal aspirate or flocked swab), and lower respiratory tract (sputum or tracheal aspirate) on daily, alternate day, or weekly basis as appropriate. Arm 2: The remainder of specimens that were submitted for laboratory investigation as part of clinical management will be retrieved. Those specimens will only be used after all clinically indicated testing and confirmation procedures have been completed. Assistance from the Public Health Laboratory Service, Department of Health, will be invited to retrieve samples as well as participate in this study. Patients hospitalized for pneumonia in medical wards and ICU at the Prince of Wales Hospital tested negative for COVID-19 will be recruited as controls. Understanding the clinical, virological, microbiological and immunological profiles of this infection is urgently needed to facilitate its management and control.
Description: Patients' treatment and management during hospitalization.
Measure: Clinical Time: 6 monthsDescription: Serial viral load changes during hospitalization.
Measure: Virological Time: 6 monthsDescription: Alterations in fecal microbiota composition (including virome, bacteria and fungi) in COVID-19 patients compared with healthy controls.
Measure: Microbiological Time: 6 monthsCurrently, limited data is available about patients with HIV in the context of the COVID-19 pandemic. People with HIV who have not achieved viral suppression through antiretroviral treatment may have a compromised immune system that leaves them vulnerable to infections and disease progression. However, little is known about the presentation and clinical outcomes of patients with HIV and SARS-CoV-2. Our aim is to characterize the clinical presentation and disease course of COVID-19 in patients with HIV.
Description: COVID-19 related death among patients with HIV and COVID-19
Measure: Mortality Time: 30 daysDescription: Percentage of patients who required hospitalization
Measure: Frequency of patients requiring hospital admissions Time: 30 daysDescription: Percentage of patients who required ICU admission
Measure: Frequency of patients requiring ICU admissions Time: 30 daysDescription: Percentage of patients who required respiratory support (new oxygen use, non-invasive ventilation,or invasive ventilation)
Measure: Frequency of respiratory support use Time: 30 daysDescription: Percentage of patients who developed acute kidney injury defined as increase in baseline creatinine, or use of renal replacement therapy
Measure: Frequency of kidney injury Time: 30 daysDescription: Percentage of patients who developed liver injury defined as increase in baseline ALT
Measure: Frequency of liver injury Time: 30 daysSince December 2019, a new agent, the SARS-Cov-2 coronavirus has been rapidly spreading from China to other countries causing an international outbreak of respiratory illnesses named COVID-19. In France, the first cases have been reported at the end of January with more than 60000 cases reported since then. A significant proportion (20-30%) of hospitalized COVID-19 patients will be admitted to intensive care unit. However, few data are available for this special population in France. We conduct a large observational cohort of ICU suspected or proven COVID-19 patients that will enable to describe the initial management of COVID 19 patients admitted to ICU and to identify factors correlated to clinical outcome.
Description: Mortality at day 28
Measure: Mortality at day 28 Time: day 28Description: severe complications (pulmonary embolism, acute kidney injury, myocarditis, cardiac arrest, liver failure, ventilator associated pneumonia) Yes / No
Measure: severe complications Time: up to day 28Description: Delay in imaging in hours
Measure: Imaging Time: day 1Description: delay in microbiological diagnosis in hours
Measure: Delay in Microbiological diagnosis Time: day 1Description: Antiviral therapy Yes / no
Measure: Antiviral therapy Time: up to day 28Description: Antibiotic therapy Yes / No
Measure: Antibiotic therapy Time: day 28Description: Covid-19 treatments Yes / No
Measure: Covid-19 treatments Time: up to day 28Description: number
Measure: Patients receiving renal replacement therapy Time: up to day 28Description: number
Measure: Patients receiving mechanical ventilation Time: up to day 28Description: Patient alive at day 28 : yes / No
Measure: Vital status Time: day 28Multicenter observational/registry study of the clinical features and outcomes of critically ill patients with COVID-19.
The current outbreak of COVID-19 pandemic has been marked by severe psychological problems. People around the world experienced a similarly frightening public health emergency, on a global scale, with the spread of this corona infection. (1) Studies of the Severe Acute Respiratory Syndrome (SARS) outbreaks that occurred in Canada, Taiwan, and Hong Kong found that the enormous emotional burden carried by those health care workers who were on the front lines of the battle against the disease led to psychological morbidity like anxiety, stress and even further leads to Post traumatic stress disorder. The initial phase of the COVID-19 outbreak in China in 2020 also reported more than half of the respondents rated the psychological impact as moderate-to-severe, and about one-third reported moderate-to-severe anxiety in general population.(2) - The chances of Fear, anxiety and stress are even higher in Individuals with preexisting liver disease as they have restriction of services for getting treatment. Moreover, they can have the following additional issues: - Fear of severe form of Corona present (as presented in most of the media and research) - Fear of dying - Added uncertainty - Family members also worried
Description: Following questionnaire will be used For Fear of COVID-19: FEAR OF COVID-19 Scale Fear of Coronavirus-19 Scale: The participants indicate their level of agreement with the statements using a five-item Likert-type scale. Answers included "strongly disagree," "disagree," "neither agree nor disagree," "agree," and "strongly agree". The minimum score possible for each question is 1, and the maximum is 5. A total score is calculated by adding up each item score (ranging from 7 to 35). The higher the score, the greater the fear of cororonavirus-19.
Measure: Assessment of the fear levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS) Time: Day 0Description: Following questionnaire will be used o For, anxiety: DASS - 21 Scale Depression, Anxiety and Stress Scale - 21 Items (DASS-21) Depression Anxiety Stress Scale (DASS)-21: The DASS-21 is based on three subscales of depression, stress, and anxiety and each subscale consists of seven questions each. Each subscale comprises of seven statements regarding how the test subject was feeling over the last week and four responses ranging from 0- did not apply to me at all, 1- applied to me some of the time, 2- applied to me for a considerable amount of time to 3- applied to me very much/most of the time. The scoring system is of the Likert type and the total score for each subscale gives the severity of that very symptom which has a range from 0 to 21 for each subscale.
Measure: Assessment of the anxiety levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS) Time: Day 0Description: Following questionnaire will be used o Stress levels: DASS - 21 Scale Depression Anxiety Stress Asymptomatic ≤4 ≤3 ≤7 Symptomatic >4 >3 >7
Measure: Assessment of the stress levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS) Time: Day 0Description: Following questionnaire will be used o For Fear of COVID-19: FEAR OF COVID-19 Scale
Measure: Association between presence of Liver disease and fear levels Time: Day 0Description: Following questionnaire will be used o For, anxiety levels: DASS - 21 Scale Depression, Anxiety and Stress Scale - 21 Items (DASS-21) Higher Scores mean worse condition
Measure: Association between presence of Liver disease and anxiety levels Time: Day 0Description: Following questionnaire will be used o For stress levels: DASS - 21 Scale Depression, Anxiety and Stress Scale - 21 Items (DASS-21) Higher Scores mean worse condition.
Measure: Association between presence of Liver disease and stress levels Time: Day 0Description: Higher Scores mean worse condition
Measure: Correlation between Fear and Child-Turcotte-Pugh Score Time: Day 0Description: Higher Scores mean worse condition
Measure: Correlation between anxiety and Child-Turcotte-Pugh Score Time: Day 0Description: Higher Scores mean worse condition
Measure: Correlation between stress and Child-Turcotte-Pugh Score Time: Day 0Description: Higher Scores mean worse condition
Measure: Correlation between fear and Model for End Stage Liver Disease Score Time: Day 0Description: Higher Scores mean worse condition
Measure: Correlation between anxiety and Model for End Stage Liver Disease Score Time: Day 0Description: Higher Scores mean worse condition
Measure: Correlation between stress and Model for End Stage Liver Disease Score Time: Day 0This is a prospective multicenter cohort study. The question arises as to whether treatment with protease inhibitors (PIs) could have a preventive role for COVID-19 infection, especially since patients living with HIV (PLWHIV) have not been described as more at risk of developing COVID-19 infection. The aim of our study will therefore be to assess the impact of long-term protease inhibitors in PLWHIV on the incidence of COVID-19.
Description: Occurrence of COVID-19 infection during the epidemics (M0, M1) in both study groups
Measure: Comparison of the incidence of COVID-19 infection in PLWHIV treated with long-term antiretroviral drugs including a protease inhibitor and those without a protease inhibitor Time: 1 monthDescription: Percentage of positive serological tests at the end of the epidemics in both study groups
Measure: Determination of the seroprevalence of COVID-19 infection in both groups of the study Time: 6 monthsDescription: Proportion of severe forms in both study groups
Measure: Comparison of the severity of COVID-19 infection symptoms in both groups of the study. Time: 6 monthsDescription: Statistical association between a risk factor and the occurrence of COVID-19 infection in both study groups
Measure: Identification of potential risk factors for COVID-19 infection in HIV patients treated with protease inhibitor or without protease inhibitor Time: 6 monthsThis study aims at investigating handwashing behavior during COVID-19 pandemic. It was hypothesized that social-cognitive and emotional predictors as well as COVID-19 morbidity and mortality rates within the country would be associated with handwashing behavior in the general population of adults in 14 countries.
Description: The 12-item self-report measure of adherence to handwashing guidelines across situations (e.g., after visiting public spaces, after touching garbage, etc.) based on the guidelines issued by the World Health Organization and the Centers for Disease Control and Prevention. The responses are provided on a 4-point scale, ranging from 1 (strongly disagree) to 4 (strongly agree). Higher scores indicate better outcomes (the higher level of adherence to handwashing guidelines).
Measure: Handwashing adherence Time: 1 monthDescription: The 1-item self-report measure of the frequency of handwashing (for at least 20 seconds, all surfaces of the hands) daily. The responses are provided on a 4-point scale, ranging from 1 (less than once) to 5 (more than 10 times). Higher scores indicate better outcomes (the higher frequency of handwashing).
Measure: Frequency of handwashing Time: 1 monthDescription: 4 self-efficacy questionnaire items; mean item score ranging from 1 to 4, higher scores indicate stronger self-efficacy
Measure: Self-efficacy Time: 1 monthDescription: 3 questionnaire items to assess risk perception; mean item score ranging from 1 to 5, higher scores indicate higher risk perception
Measure: Risk perception Time: 1 monthDescription: 4 items assessing positive (1 item) and negative (1 items) outcome expectancies; mean item scores ranging from 1 to 4, higher scores indicate more positive outcome expectancies
Measure: Outcome expectancy Time: 1 monthDescription: 2 questionnaire items assessing intention to adhere to handwashing recommendations; mean item scores ranging from 1 to 4, higher scores indicate stronger intention to wash hands (for at least 20 seconds, all surfaces of the hands)
Measure: Intention Time: 1 monthDescription: 2 questionnaire items assessing action planning (1 item) and coping planning (1 item); mean item scores ranging from 1 to 4, higher scores indicate a higher level of self-reported planning
Measure: Planning Time: 1 monthDescription: 3 questionnaire items assessing a facet of action control, namely self-monitoring; mean item scores ranging from 1 to 4, higher scores indicate a higher level of self-reported monitoring of handwashing behavior
Measure: Action control Time: 1 monthDescription: 1 questionnaire item assessing perceptions of handwashing as an effective means of preventing coronavirus SARS-CoV-2 infection; item scores ranging from 1 to 4, higher scores indicate a higher level of perceived effectiveness of hand hygiene
Measure: Perceived effectiveness of hand hygiene Time: 1 monthDescription: 7-item self-report scale (Generalized Anxiety Disorder, GAD-7) scale to assess anxiety symptoms; mean item scores ranging from 1 to 4, higher scores indicate a higher level of generalized anxiety
Measure: Anxiety Time: 1 monthDescription: The daily cumulative numbers for COVID-19 morbidity and mortality in the study countries. Published daily as the Situation Report by World Health Organization, starting on 21 January 2020. Higher numbers indicate the higher cumulative COVID-19 morbidity and mortality rates in the country.
Measure: Country-level COVID-19 morbidity and mortality rates Time: 60 daysHospital staff and emergency personnel are expected to suffer impaired psychological outcomes during a pandemic in terms of Quality of Life, anxiety, depression or other outcomes. The Covid-19 pandemic is a threat for both somatic and psychological health, therefore the impact of the impairment of this event on psychological parameters has to be assessed.
Description: Validated 20-items questionnaire for PTSD
Measure: PCL5 Questionnaire Time: 14 daysDescription: The Brief Symptom Inventory (BSI) is a 53-item screener for mental health problems with 9 subscales.
Measure: BSI - Brief symptom inventory Time: 14 daysDescription: Instrument for psychological diagnostics, able to test the severity of mental disorders and the success of their treatment
Measure: PHQD Time: 14 daysDescription: Qol Questionnaire, assessed QoL with respect to the individual's perceptions in the context of culture and value systems.
Measure: WHO - QoL BREF Time: 14 daysDescription: The State-Trait Anger Expression Inventory is used to measure the expressions & control of anger
Measure: STAXI Time: 14 daysDescription: The AUDIT questionnaire is designed to help in the self assessment of alcohol consumption
Measure: AUDIT questionnaire Time: 14 daysTo compare various treatments provided to positive COVID-19 patients at locations across the OSF Ministry. Provide the opportunity to compare the effectiveness of various treatments and treatment timelines provided to specific cohorts of patients that have the potential to impact future treatment plans for COVID-19 patients and/or future research hypotheses.
This prospective observational study examines the effects of the Covid-19 pandemic on oral health, taking psychosocial factors into account, and the possible impact of a high periodontitis risk on the severity of the need for treatment in Covid-19 patients.
Description: The survey consists of validated and unvalidated items giving the opportunity to assess periodontitis risk, psychosocial stress, anxiety, depression and oral health related quality of life as well as questions focusing on experiences of the covid-19 pandemic.
Measure: How do people assess their oral health-related quality of life in times of the Covid-19 pandemic? Time: 08.05.2020-31.07.2020Description: The survey consists of validated and unvalidated items giving the opportunity to assess periodontitis risk, psychosocial stress, anxiety, depression and oral health related quality of life as well as questions focusing on experiences of the covid-19 pandemic.
Measure: Does the periodontitis risk have an influence on the severety of the Covid-19 disease and its' treatment? Time: 08.05.2020-31.07.2020Description: The survey consists of validated and unvalidated items giving the opportunity to assess periodontitis risk, psychosocial stress, anxiety, depression and oral health related quality of life as well as questions focusing on experiences of the covid-19 pandemic.
Measure: Do psychosocial stress factors in times of the Covid-19 pandemic have an impact on their oral health related quality of life? Time: 08.05.2020-31.07.2020Description: The survey consists of validated and unvalidated items giving the opportunity to assess periodontitis risk, psychosocial stress, anxiety, depression and oral health related quality of life as well as questions focusing on experiences of the covid-19 pandemic.
Measure: Have people changed their oral hygiene practices in times of the Covid-19 pandemic? Time: 08.05.2020-31.07.2020This study will describe the recovery process of patients undergoing cardiac surgery during the covid-19 pandemic. This will focus on hemodynamic failure and organ dysfunction after surgery. Capturing real-world data and sharing international experience will inform the management of this complex group of patients who undergo surgery throughout the COVID-19 pandemic, improving their clinical care. This investigator-led, non-commercial, non-interventional does not collect any patient identifiable information.
Description: The VIS score correlates with mortality after cardiac surgery and reflects the degree of patient hemodynamic failure. This score is calculated as follows: ISR = Dobutamine dose in g/kg/min + 100 times the Adrenaline dose in g/kg/min + 100 times the Noradrenaline dose in g/kg/min + 10,000 times the Vasopressin dose in U/kg/min.
Measure: Highest VIS (Vasoactive-Inotropic Score) in the first 12 hours postoperatively. Time: 12 hours post-operativelyDescription: Prospective assessment of ICU outcomes until all included patients were discharged from ICU
Measure: Post-operative organ failure Time: 5 days post-operativelyDescription: Prospective assessment of ICU outcomes until all included patients.
Measure: Post-operative outcome Time: 28 days post-operativelyThe outbreak of coronavirus was categorized as a global pandemic in March 2020. The Danish government recommends social distancing during the COVID-19 pandemic. Long-term social distancing and fear of disease can lead to anxiety, depression and the feeling of loneliness. All these factors might affect the quality of life (QoL). The aim of this study is to investigate the overall QoL for patients with cancer during the COVID-19 pandemic with special focus on emotional functioning.
Description: EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30 (Quality of Life Questionnaire core 30) - The QLQ-C30 is a standardized cancer-specific 30-itemed instrument. Scores are transformed linearly to a zero to 100 scale. A higher score on the functional scale and the global Health related Quality of Life indicates better functioning. In the current study, the items addressing global quality of life and health: "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" will be used to get a pure expression of QoL. The EORTC QLQ-C30 scores in this study will be compared with QoL for Danish Cancer patients in the period before COVID-19 (https://www.cancer.dk/dyn/resources/File/file/3/8373/1574778638/kraeftens-bekaempelses-barometerundersoegelse-2019.pdf). Results on overall QoL is listed on page 36.
Measure: Overall Quality of Life Time: One measurement of EORTC QLQ-C30 and a survey created for the purpose will be performed through study completion, an average of 1 monthsThe current project is a prospective, multicentric cohort study aiming at a multidisciplinary assessment (pulmonary, cardiometabolic, sleep and mental health) of the consequences of infection by SARS-CoV-2, 3 months after the diagnosis in order to better characterize these complications. 400 patients with a positive diagnosis of SARS-CoV-2 will be included in the study 3 months after their diagnosis: They will be followed at 6 months, 1 year, 3 years, and 5 years, as function of their after-effects discovered at 3 months and their evolution.
Description: Pulmonary function 3 months after COVID diagnosis, as measured by diffusion capacity of carbon monoxide (DLCO)
Measure: Diffusion Capacity for Carbon Monoxide (CO) 3 months after COVID diagnosis Time: 3 months after COVID diagnosisDescription: Prevalence of Sleep Disordered Breathing, as measured by polysomnography
Measure: Prevalence of Sleep Disordered Breathing (SDB) 3 months after COVID diagnosis Time: 3 months after COVID diagnosisDescription: Prevalence of sleep disorders, as measured by polysomnography
Measure: Prevalence of sleep disorders 3 months after COVID diagnosis Time: 3 months after COVID diagnosisDescription: Prevalence of ventilatory impairments measured by pulmonary function tests
Measure: Prevalence of ventilatory muscle function impairments, 3 months after COVID diagnosis Time: 3 months after COVID diagnosisDescription: Prevalence of cardiac impairments measured by cardiac echography
Measure: Prevalence of cardiac impairments 3 months after COVID diagnosis Time: 3 months after COVID diagnosisDescription: Pulmonary function as measured by diffusion capacity of carbon monoxide (DLCO)
Measure: Follow-up of pulmonary diffusion capacity of carbon monoxide Time: From Baseline (3 months after COVID diagnosis) to 5 yearsDescription: Assessment of SDB treatments adherence will be monitored in hours/night
Measure: Follow-up of sleep disorders treatment compliance Time: From Baseline (3 months after COVID diagnosis) to 5 yearsDescription: Assessment of SDB treatments efficacy will be based on the residual AHI index (Apnea Hypopnea/hour) under treatment
Measure: Follow-up of sleep disorders treatments efficacy Time: From Baseline (3 months after COVID diagnosis) to 5 yearsDescription: HLA alleles will be assessed as a component of genetic immune capacity
Measure: HLA alleles aspect of COVID clinical presentation Time: 3 months after COVID diagnosisDescription: KIR loci will be assessed as a different component of genetic immune capacity
Measure: KIR loci aspect of COVID clinical presentation Time: 3 months after COVID diagnosisDescription: metabolome expression in sera
Measure: metabolomic aspect of COVID clinical presentation Time: 3 months after COVID diagnosisAs dentists begin reopening their practices during a global pandemic, the risk of COVID-19 infection that dentists face in providing dental care remains unknown. Estimating the occupational risk of COVID-19, and producing evidence on the types of infection control practices and dental practices that may affect COVID-19 risk, is therefore imperative. The goal of the proposed study is to understand U.S.-based dentists' health and dental-practice reactions to COVID-19. To estimate this, U.S-based dentists will be surveyed monthly. These findings could be used to describe the prevalence and incidence of COVID-19 among dentists, determine what infection control steps dentists take over time, and estimate whether infection control adherence in dental practice is related to COVID-19 incidence.
Description: COVID-19 case as confirmed by clinician and/or detection of SARS-CoV-2 RNA or a specific antigen in a clinical specimen
Measure: COVID-19 probable or confirmed case Time: 18 monthsDescription: Assessed using the Patient Health Questionnaire for Depression and Anxiety (PHQ-4). Two items scored 0 to 3 (total score of 0-6), with higher numbers indicating greater anxiety.
Measure: Anxiety Time: 12 monthsDescription: Assessed using the Patient Health Questionnaire for Depression and Anxiety (PHQ-4). Two items scored 0 to 3 (total score of 0-6), with higher numbers indicating greater depressive symptoms.
Measure: Depression Time: 12 monthsDescription: Self-reports of infection control efforts in the respondents' primary dental practices
Measure: Dental practice infection control efforts Time: 12 monthsDescription: Self-reports of personal protective equipment use
Measure: Dentists' use of personal protective equipment Time: 12 monthsThe study cohort will be enrolled among all Humanitas group employees (including ICH, Humanitas University and Gavazzeni), and two validation cohorts. Participants will be asked consent for the research use of blood, pharyngeal swab, and for those hospitalized for COVID-19, also for the bronchoalveolar lavage and fecal samples. Biological samples will be used to perform cellular, microbial and molecular analyses aimed at better understanding the disease pathogenesis and the individual differences in susceptibility to the disease.
Description: COVID-19 infection will be assessed by serological analysis of the presence of IgG anti-Covid-19 antibodies, an a subsequent pharyngeal swab. Symphtoms and possible hospitalization will be considered in clinical response.
Measure: Clinical response to COVID-19 Time: 36 monthsDescription: PBMC analysis by FACS to investigate the immunophenotype and correlate it to the clinical outcome (symptoms aggressiveness).
Measure: Immunological response to COVID-19 Time: 36 monthsDescription: Genetic variants analysis potentially related with COVID-19 susceptibility/severity in different subgroups of patients, ranging from individuals positive for the virus but asymptomatic to individuals affected by COVID-19 with ARDS requiring admission to ICU
Measure: Genetic predisposition to COVID-19 Time: 36 monthsDescription: Microbiota analysis (using 16S rDNA sequencing technology) of residual BAL, pharyngeal swab, plasma and saliva/sputum to evaluate whether different microbial or metabolome profiles are associated to worsen disease or to protection
Measure: Microbiome-related response to COVID-19 Time: 36 monthsSARS-CoV-2 is the novel coronavirus responsible for COVID-19, coronavirus disease 2019. This new coronavirus was first detected in Wuhan, China in late December 2019. According to WHO, the incidence rate of COVID-19 is prominent among adults and elderly people, reaching so far >2 million cases globally. Meanwhile, confirmed death cases reached >126 thousands of reported cases in 185 countries and still increasing. We anticipate that immunological differences among COVID19-infected patients might be a reason behind the variation of patient outcomes. Therefore, we intend to investigate cellular and humoral immune responses of COVID19-positive patients, and we claim to discover new indicators of patients' prognosis. Our target population includes three categories of patients staying at ICU, HMC (COVID19-positive vs. COVID19-negative vs. healthy control). Throughout their ICU stay, multiple blood samples will be screened for leukocytes surface markers, leukocytes' production of certain molecules, and circulating cytokines/chemokines/checkpoint inhibitors. Their plasma/serum will be used as well for immune proteomics, metabolomics, and other serological tests. Such parameters can provide the more comprehensive status of COVID19-infected patients at infection onset, during treatment intake, and at recovery or relapse stage. Following analysis, the main prospective outcome of this study is to identify the most reflective markers of COVID19-positive patients' outcomes.
Description: A descriptive analysis of the innate and adaptive immune cells (phenotypically and functionally), along with circulating pro- and anti-inflammatory cytokines, and the dynamic change of immune cells and cytokines throughout the first 4 weeks of the COVID-19 infection.
Measure: To create an immune profile for each COVID19-positive patient during their ICU stay Time: 8 to 12 monthsDescription: A correlative analysis of the immune cells and cytokines levels with the COVID-19 severity and with the patient's outcome following their stay at the ICU. An attempt to identify markers associated with the disease severity and predictive measures to the patient's outcome.
Measure: To correlate patients' immune profile to disease severity and patient's outcome Time: 4 to 6 monthsThis is a multi-center study comparing clinical outcomes in patients with COVID-19 in subjects hospitalized at Hadassah and other hospitals for PCR or serology confirmed COVID-19 and compare the outcomes to the presence of different degrees of a cytokine storm. The patients will be subdivided into a mild, moderate, and severe course according to NEWS2.
Description: To compare the clinical outcomes of patients with COVID-19 to Sepsis and CAR-T-related cytokine storm. This will be done by assessment of acute-illness severity using the NEWS2 scoring system (Higher scores mean more severe illness)
Measure: Clinical Outcomes of Patients with COVID-19 using the National Early Warning Score 2 (NEWS2) system Time: 6 monthsDescription: To compare the clinical outcomes of patients with COVID-19 to Sepsis and CAR-T-related cytokine storm. This will be done by assessment of acute-illness severity using the new NIH Patient Classification to (1) Asymptomatic or Pre-symptomatic Infection; (2) Mild Illness; (3) Moderate Illness; (4) Severe Illness; (5) Critical Illness As detailed in the Study design section.
Measure: Clinical Outcomes of Patients with COVID-19 using the new NIH Patient Classification of severity of illness Time: 6 monthsDescription: Incidence rate of Mortality from any cause
Measure: Mortality Time: 6 monthsDescription: To assess cytokine/chemokine/hematopoietic growth factors/ Complement and other immune modulators in patients with COVID-19 by measuring the serum concentrations of these factors in COVID-19 patients and compare those the levels of patients with sepsis and CAR T cytokine release syndrome.
Measure: Cytokine/Chemokine/Hematopoietic Growth Factors/ Complement and Other Immune Modulators in Patients with COVID-19 Time: 6 monthsThe current Coronavirus Disease 2019 (COVID-19) pandemic has resulted in extraordinary public health orders of social distancing and self-isolation, leading to widespread disruption and discontinuation of cardiac rehabilitation programmes and other social opportunities for cardiovascular disease (CVD) patients to exercise. In Austria, the government initiated drastic public health measures on March 10, 2020, closing all outpatient cardiac rehabilitation facilities and restricting inpatient rehabilitation to patients with urgent medical indications only. This study aims to explore the impact of COVID-19-related national lockdown and public health restrictions on cardiac rehabilitation patients, with respect to maintenance of physical activity for secondary CVD prevention. The study poses three research questions, which will be addressed in a mixed-methods study with sequential quantitative-qualitative (QUANT-QUAL) design: 1. What was the impact of the COVID-19-related lockdown on patients' physical activity and physical fitness levels? (QUANT stage) 2. What was the patient experience of the closure of group-based cardiac rehabilitation training due to COVID-19 public health restrictions? (QUAL stage) 3. Which insights and learning points may be drawn from patients' experiences during COVID-19 public health restrictions with respect to the provision of home-based digital support for physical activity? (QUAL stage) The study will recruit a cohort of up to 40 cardiac rehabilitation patients from one outpatient cardiac rehabilitation centre in Salzburg, Austria, whose rehabilitation programme was interrupted by COVID-19 public health orders, including "lockdown". Patients will undergo re-assessment of physical fitness in cycle ergometry test and re-assessment of cardiovascular risk profile. This will be compared with patients' most recent available test results from before the COVID-19 lockdown (i.e. prior to mid-March 2020) from patient records. Additionally, patients will take part in a semi-structured qualitative interview in which they will be invited to reflect on their personal experiences during the COVID-19 lockdown and thereafter.
Description: Maximal work load (W) achieved in cycle ergometry test
Measure: Work load (W) Time: up to 12 monthsDescription: Maximal work load (W) achieved in cycle ergometry test expressed as percentage of predicted value
Measure: Work load % of predicted value Time: up to 12 monthsDescription: Maximal heart rate (bpm) during cycle ergometry test
Measure: Heart rate (bpm) Time: up to 12 monthsDescription: Range 1% to 29%, higher percentage indicating worse risk estimate
Measure: Framingham Recurrent Coronary Heart Disease risk score Time: up to 12 monthsDescription: MET-minutes/week calculated from patient self-report of physical activity (International Physical Activity Questionnaire, IPAQ, 7 day version)
Measure: Metabolic Equivalent (MET) minutes / week Time: up to 12 monthsDescription: Semi-structured qualitative interview
Measure: Patient Experience Time: 5 monthsNovel coronavirus 2019 (COVID-19) has emerged as a major international public health concern. While much of the morbidity and mortality associated with COVID-19 has been attributed to acute respiratory distress syndrome (ARDS) or end-organ failure, emerging data suggest that disorders of coagulation, in particular hypercoagulability and venous thromboembolism (VTE), may represent an additional major, and possibly preventable, complication (Wu C, et al. JAMA Intern Med. 2020 Mar 13. [Epub ahead of print] and Tang N, et al. Thromb. Haemost. 2020 Feb 19. [EPub Ahead of Print]). Abnormal coagulation testing results, especially markedly elevated D-dimer and FDP, have been associated with a poor prognosis in COVID-19 infection. We propose the following Electronic Health Record (EHR)-guided 10000-patient, retrospective observational cohort study to assess VTE incidence, risk factors, prevention and management patterns, and thrombotic outcomes in patients with COVID-19 infection. In order to gain the valuable perspective of other regional and national centers providing care for large populations of COVID-19, we have started a collaborative network with 5 additional sites which will provide us with de-identified data from 1000 patients each. These 5000 patients in addition to the 5000-patient cohort we are enrolling within the Mass General Brigham Network will comprise this study population.
Description: Frequency (%) of arterial or venous thromboembolism
Measure: Frequency of arterial or venous thromboembolism over 30 days Time: 30 daysDescription: Frequency (%) of arterial or venous thromboembolism
Measure: Frequency of arterial or venous thromboembolism over 90 days Time: 90 daysDescription: Frequency (%) of all-cause death, bleeding, and thromboembolic outcomes
Measure: Frequency of all-cause death, bleeding, and thromboembolic outcomes at 30 days Time: 30 daysDescription: Frequency (%) of all-cause death, bleeding, and thromboembolic outcomes
Measure: Frequency of all-cause death, bleeding, and thromboembolic outcomes at 90 days Time: 90 daysAs dental practices reopen their practices during a global pandemic, the risk of 2019 novel coronavirus (COVID-19) infection that dental hygienists face in providing dental care remains unknown. Estimating the occupational risk of COVID-19, and producing evidence on the types of infection control practices and dental practices that may affect COVID-19 risk, is therefore imperative. These findings could be used to describe the prevalence and incidence of COVID-19 among dental hygienists, determine what infection control steps dental hygienists take over time, describe dental hygienists' employment during the COVID-19 pandemic, and estimate whether infection control adherence in dental practice is related to COVID-19 incidence.
Description: 2019 novel coronavirus (COVID-19) case as confirmed by clinician and/or detection of SARS-CoV-2 antigen or antibody
Measure: COVID-19 probable or confirmed case Time: 18 monthsDescription: Assessed using the Patient Health Questionnaire for Depression and Anxiety (PHQ-4). Two items scored 0 to 3 (total score of 0-6), with higher numbers indicating greater anxiety.
Measure: Anxiety Time: 12 monthsDescription: Assessed using the Patient Health Questionnaire for Depression and Anxiety (PHQ-4). Two items scored 0 to 3 (total score of 0-6), with higher numbers indicating greater depressive symptoms.
Measure: Depression Time: 12 monthsDescription: Self-reports of infection control efforts in the respondents' primary dental practices.
Measure: Dental practice infection control efforts Time: 12 monthsDescription: Availability, frequency of use, and frequency of reuse of personal protective equipment
Measure: Personal protective equipment Time: 12 monthsDescription: Self-descriptions of current level of employment as a dental hygienist and reasons for non-employment.
Measure: Employment status Time: 12 monthsQuarantine separates persons who have been potentially exposed to an infectious agent (and thus at risk for disease) from the general community. However, it may create psychological, emotional, and financial problems for some persons. The experience of those placed under quarantine in terms of compliance, difficulties, emotional response and psychological impact remains under-researched. In view of the increasing cases of COVID-19 in India and the rising numbers of people being quarantined as a precautionary measure, it was imperative to assess those quarantined for the psychological impact of the concerns regarding this illness and the quarantine procedure. In India, no such study had been undertaken and our study thus filled the research gap. The cross-sectional observational study aims at assessing the psychological impact of quarantine on Indian BSF jawans (n=100). They would be assessed for depression, anxiety, perceived stress level of impact, and impact of life events using Beck Depression Inventory, State Trait Anxiety Inventory, Perceived Stress Scale, and Impact of Events Scale-Revised. A qualitative interview schedule will also be carried out. Data would be analysed.
Description: Beck Depression Inventory
Measure: depression Time: BaselineDescription: State Trait Anxiety Inventory
Measure: anxiety Time: BaselineDescription: Perceived Stress Scale
Measure: perceived stress Time: BaselineDescription: Impact of Events Scale-Revised
Measure: impact of life events Time: BaselineThe COVID-19 pandemic has exposed the unwanted variation in outcomes as evidence by Public Health England's report on increased mortality in regions of the country. For example, UHDB, in East Midlands, has reported a high crude mortality as compared to other Trusts in the region.8 There may also have been variation in the incidence of complications of COVID-19 in the form of AKI, which may have influenced mortality. Variation in outcomes may be because of various factors - differing population demographics, underlying health conditions in the population, deprivation, physician preference and knowledge and ethnic diversity. Unwanted variation is care that is not consistent with a patient's preference or related to [their] underlying illness. It is important to understand the reason for unwanted variation in outcomes associated with COVID-19 to minimise patient harm and reduce morbidity and mortality.
Description: In-hospital all cause mortality in patients with acute kidney injury and COVID-19
Measure: All-cause mortality Time: 30 daysDescription: Incidence of acute kidney injury in patients with COVID-19
Measure: acute kidney injury Time: 30 daysDescription: Need for mechanical ventilation in patients with COVID-19
Measure: Mechanical ventilation Time: 30 daysThis is a prospective observational parallel group cohort study that will aim to recruit 220 participants who were admitted to the hospital with COVID-19 between 1st March 2020 and 30th June 2020 (Group A - 110 participants who had COVID-19 with AKI; Group B - 110 participants who had COVID-19 without AKI). Data from groups A and B will be compared with AKI and non-AKI groups from an existing study database (ARID study, n=1125) who were recruited before the outbreak of the COVID-19 pandemic (recruitment 2013-2016) and who have all completed at least three years of follow up. Participants who have recovered from COVID-19 will be matched for analysis to participants from the ARID study for AKI status, baseline estimated glomerular filtration rate (eGFR) stage, age (± 5 years) and presence of diabetes. Potential participants will receive a letter of invitation along with a comprehensive participant information sheet (PIS).
Description: Kidney disease progression will be defined as a decline in estimated glomerular filtration rate (eGFR; ml/min/1.73m2) of ≥30%
Measure: Incidence of kidney disease progression at 12 months. Time: 12 months after hospital discharge.Description: Albuminuria will be defined as a urine albumin to creatinine ratio (UACR) of >30mg/mmol.
Measure: Incidence of albuminuria at 6-9 months. Time: 6-9 months after hospital discharge.Description: Albuminuria will be defined as a urine albumin to creatinine ratio (UACR) of >30mg/mmol.
Measure: Incidence of albuminuria at 12-15 months. Time: 12-15 months after hospital discharge.Description: Combined kidney disease progression outcome of ≥30% decline in eGFR (ml/min.1.73m2) and/or albuminuria (UACR>30mg/mmol).
Measure: Incidence of combined kidney disease progression and albuminuria at 6-9 months. Time: 6-9 months after hospital discharge.Description: Combined kidney disease progression outcome of ≥30% decline in eGFR (ml/min.1.73m2) and/or albuminuria (UACR>30mg/mmol).
Measure: Incidence of combined kidney disease progression and albuminuria at 12-15 months. Time: 12-15 months after hospital discharge.Description: Multi-variable Cox proportional hazards models will be used to assess the factors associated with all-cause mortality
Measure: Factors associated with all-cause mortality at 6-9 months. Time: 6-9 months after hospital discharge.Description: Multi-variable Cox proportional hazards models will be used to assess the factors associated with all-cause mortality
Measure: Factors associated with all-cause mortality at 12-15 months. Time: 12-15 months after hospital discharge.Description: Number of hospital readmissions
Measure: Incidence of hospital readmissions at 6-9 months Time: 6-9 months after hospital discharge.Description: Number of hospital readmissions
Measure: Incidence of hospital readmissions at 12-15 months Time: 12-15 months after hospital discharge.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports